SG10201912099TA - Engineered botulinum neurotoxins - Google Patents
Engineered botulinum neurotoxinsInfo
- Publication number
- SG10201912099TA SG10201912099TA SG10201912099TA SG10201912099TA SG10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA SG 10201912099T A SG10201912099T A SG 10201912099TA
- Authority
- SG
- Singapore
- Prior art keywords
- botulinum neurotoxins
- engineered botulinum
- engineered
- neurotoxins
- botulinum
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347579P | 2016-06-08 | 2016-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912099TA true SG10201912099TA (en) | 2020-02-27 |
Family
ID=59227906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810210UA SG11201810210UA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
| SG10201912099TA SG10201912099TA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810210UA SG11201810210UA (en) | 2016-06-08 | 2017-06-08 | Engineered botulinum neurotoxins |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11104891B2 (en) |
| EP (1) | EP3468985A1 (en) |
| JP (2) | JP7152392B2 (en) |
| KR (1) | KR20190025906A (en) |
| CN (1) | CN109476713A (en) |
| AU (1) | AU2017277905B2 (en) |
| BR (1) | BR112018075363A2 (en) |
| CA (1) | CA3026492A1 (en) |
| EA (1) | EA201892784A1 (en) |
| IL (1) | IL263058B2 (en) |
| MX (1) | MX2018015254A (en) |
| SG (2) | SG11201810210UA (en) |
| WO (1) | WO2017214447A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3372239T3 (en) | 2012-05-30 | 2021-02-01 | Harvard College | MANIPULATED BOTULINUM NEUROTOXIN |
| EP3274364B1 (en) * | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| TW201718627A (en) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| MX2018014066A (en) * | 2016-05-16 | 2019-04-04 | Harvard College | Method for purification and activation of botulinum neurotoxin. |
| HUE061429T2 (en) * | 2016-07-08 | 2023-06-28 | Childrens Medical Center | A novel botulinum neurotoxin and its derivatives |
| US11117935B2 (en) | 2016-08-24 | 2021-09-14 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| WO2019067815A2 (en) | 2017-09-29 | 2019-04-04 | Children's Medical Center Corporation | A neurotoxin-like toxin and uses thereof |
| TWI810228B (en) * | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | Treatment of autonomic disorders |
| KR20200115584A (en) * | 2018-01-30 | 2020-10-07 | 칠드런'즈 메디컬 센터 코포레이션 | Production of botulinum neurotoxin using the Bacillus system |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| CN114957482B (en) * | 2021-02-26 | 2024-09-24 | 重庆誉颜制药有限公司 | Single-chain polypeptide of modified neurotoxin and application thereof |
| KR20230001254A (en) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods |
| KR20230001260A (en) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods |
| WO2023068485A1 (en) * | 2021-10-22 | 2023-04-27 | 비피메드(주) | Composition for ameliorating hair loss comprising botulinum-derived peptide |
| KR20240116485A (en) * | 2021-11-22 | 2024-07-29 | 입센 바이오팜 리미티드 | treatment of pain |
| CN114369623B (en) * | 2022-01-12 | 2023-07-07 | 中国人民解放军空军军医大学 | Syntagmin 2-RNAi based on Cre-lox recombination system and application thereof |
| CN114410683B (en) * | 2022-01-12 | 2023-11-28 | 中国人民解放军空军军医大学 | RIM3-RNAi based on Cre-lox recombination system and application thereof |
| GB202206348D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| KR20240051355A (en) * | 2022-10-12 | 2024-04-22 | 주식회사 알케미어 | Light chain mutants of Botulinum toxin |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4921757A (en) | 1985-04-26 | 1990-05-01 | Massachusetts Institute Of Technology | System for delayed and pulsed release of biologically active substances |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| JPH0825869B2 (en) | 1987-02-09 | 1996-03-13 | 株式会社ビタミン研究所 | Antitumor agent-embedded liposome preparation |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
| EP0758900B1 (en) | 1994-05-09 | 2002-04-10 | BINDER, William J. | Botulinum toxin FOR REDUCTION OF migraine HEADACHE PAIN |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5721215A (en) | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| DE102005019302A1 (en) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier for targeting nerve cells |
| US9303080B2 (en) * | 2006-01-13 | 2016-04-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| US8273865B2 (en) | 2006-03-15 | 2012-09-25 | Allergan, Inc. | Multivalent clostridial toxins |
| DK3372239T3 (en) * | 2012-05-30 | 2021-02-01 | Harvard College | MANIPULATED BOTULINUM NEUROTOXIN |
| US9913875B2 (en) | 2015-03-16 | 2018-03-13 | California Institute Of Technology | Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2017
- 2017-06-08 SG SG11201810210UA patent/SG11201810210UA/en unknown
- 2017-06-08 CN CN201780035648.4A patent/CN109476713A/en active Pending
- 2017-06-08 JP JP2019516917A patent/JP7152392B2/en active Active
- 2017-06-08 US US16/308,146 patent/US11104891B2/en active Active
- 2017-06-08 IL IL263058A patent/IL263058B2/en unknown
- 2017-06-08 EA EA201892784A patent/EA201892784A1/en unknown
- 2017-06-08 CA CA3026492A patent/CA3026492A1/en active Pending
- 2017-06-08 MX MX2018015254A patent/MX2018015254A/en unknown
- 2017-06-08 BR BR112018075363-7A patent/BR112018075363A2/en not_active IP Right Cessation
- 2017-06-08 KR KR1020197000585A patent/KR20190025906A/en not_active Application Discontinuation
- 2017-06-08 WO PCT/US2017/036628 patent/WO2017214447A1/en unknown
- 2017-06-08 SG SG10201912099TA patent/SG10201912099TA/en unknown
- 2017-06-08 AU AU2017277905A patent/AU2017277905B2/en active Active
- 2017-06-08 EP EP17733667.4A patent/EP3468985A1/en not_active Withdrawn
-
2022
- 2022-03-18 JP JP2022044568A patent/JP2022112031A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017277905B2 (en) | 2022-04-14 |
| SG11201810210UA (en) | 2018-12-28 |
| US11104891B2 (en) | 2021-08-31 |
| KR20190025906A (en) | 2019-03-12 |
| WO2017214447A1 (en) | 2017-12-14 |
| JP7152392B2 (en) | 2022-10-12 |
| MX2018015254A (en) | 2019-08-16 |
| AU2017277905A1 (en) | 2018-12-20 |
| JP2022112031A (en) | 2022-08-01 |
| JP2019523015A (en) | 2019-08-22 |
| IL263058B2 (en) | 2023-11-01 |
| EP3468985A1 (en) | 2019-04-17 |
| CN109476713A (en) | 2019-03-15 |
| US20190300869A1 (en) | 2019-10-03 |
| EA201892784A1 (en) | 2019-05-31 |
| CA3026492A1 (en) | 2017-12-14 |
| BR112018075363A2 (en) | 2019-03-19 |
| IL263058B1 (en) | 2023-07-01 |
| IL263058A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263058A (en) | Engineered botulinum neurotoxins | |
| HK1249119A1 (en) | Engineered botulinum neurotoxin | |
| IL262575B (en) | Chimeric neurotoxins | |
| ZA201900341B (en) | A novel botulinum neurotoxin and its derivatives | |
| HK1245292A1 (en) | Cationic neurotoxins | |
| GB201621111D0 (en) | Neurotoxins | |
| SG11201607400VA (en) | Manufacture of recombinant clostridium botulinum neurotoxins | |
| IL253429A0 (en) | Botulinum toxin prefilled container | |
| PL3411389T3 (en) | New streptococcal proteases | |
| IL252749B (en) | Botulinum toxin prefilled container | |
| IL259185B (en) | Thrombin microcapsules | |
| HK1249147A1 (en) | Methods for enhancing the specific uptake of botulinum neurotoxins into cells | |
| EP3615669A4 (en) | Botulinum neurotoxins production methods | |
| PL3458583T3 (en) | Improved-performance proteases | |
| GB201603320D0 (en) | Enhancing photosynthesis | |
| SG11201705547SA (en) | Static switch | |
| EP3612154A4 (en) | Botulinum neurotoxins for treating hyperhidrosis | |
| GB201600979D0 (en) | Jft | |
| GB201609127D0 (en) | Protease variants and uses thereof |